Back to Clinical Trials

Clinical Trials: Clinical Immunology


Source: Baxalta US Inc.
The purpose of the study is to acquire additional data on safety and tolerability of recombinant human hyaluronidase (rHuPH20) facilitated subcutaneous treatment of Immune Globulin Infusion (Human), 10% (IGI, 10%) and to assess the mode of product administration. Read More
Last Updated: 25 Jun 2015
Source: Baxalta US Inc.
The purpose of the study is to develop a 20% subcutaneous immunoglobulin treatment option for patients with primary immunodeficiency (PID) diseases. Read More
Last Updated: 25 Jun 2015
Source: Shire
This study is being conducted to evaluate the efficacy and safety of icatibant compared to placebo in patients experiencing acute attacks of hereditary angioedema (HAE). Read More
Last Updated: 10 Sep 2014
Source: Baxalta US Inc.
The purpose of this study is to assess the safety and efficacy of Immune Globulin Intravenous (Human), 10% (IGIV 10%) in subjects with primary immunodeficiency disorders. Read More
Last Updated: 25 Jun 2015
Source: Baxalta US Inc.
The purpose of this study is to develop a 20% subcutaneous (SC) immunoglobulin preparation for the treatment of patients with primary immunodeficiency diseases (PIDD). Read More
Last Updated: 05 May 2016
Source: Baxalta US Inc.
The purpose of the proposed study is to acquire additional data (including the assessment of anti-rHuPH20 antibodies) on the long-term safety of HYQVIA and to assess the prescribed treatment regimens and treatment administration in routine clinical practice. Read More
Last Updated: 01 Oct 2016
Source: University of Toronto
A non-randomized, interventional, longitudinal clinical study to quantify the impact of bacterial vaginosis treatment on HIV susceptibility and genital immunology in Kenyan women. Read More
Last Updated: 08 Feb 2016
Source: Shire
The study objective was to evaluate the safety and efficacy of prophylactic use of C1INH-nf for the prevention of acute HAE attacks. Read More
Last Updated: 18 Mar 2014
Source: Pharming Technologies B.V.
This study is being conducted to confirm the efficacy, safety, and immunogenicity of recombinant human C1 inhibitor (rhC1INH) at a dose of 50 U/kg when used for the treatment of acute angioedema attacks in Hereditary Angioedema (HAE) patients. Read More
Last Updated: 02 Aug 2015
Source: Pharming Technologies B.V.
Primary Objective: To evaluate the efficacy of recombinant human C1 inhibitor (rhC1INH) in the prophylaxis of angioedema attacks in patients with HAE Secondary Objective: To evaluate the safety and immunogenicity of recombinant human C1 inhibitor (rhC1INH) in the prophylaxis of angioedema attacks in patients with HAE Read More
Last Updated: 13 Oct 2016
Source: National Cancer Institute (NCI)
RATIONALE: Studying samples of blood or tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. PURPOSE: This clinical trial studies prostate-specific antigen (PSA) antibody levels in samples from patients treated for prostate cancer on trial ECOG-E9802. Read More
Last Updated: 22 Aug 2012
Source: Shire
The objective of this study is to evaluate the formation of antibodies, the occurence of allergic reactions, and the risk of hypercoagulability and hypocoagulability in patients treated with KALBITOR (ecallantide). Read More
Last Updated: 27 Jun 2016
Source: Shire
This study is being conducted to explore the clinical safety, local tolerability, convenience and effectiveness of self-treatment of hereditary angioedema (HAE) attacks with subcutaneous injections of icatibant. Read More
Last Updated: 29 Jun 2014
Source: NIH AIDS Clinical Trials Information Service
To confirm results from a previous study in which the combination of thymopentin plus zidovudine ( AZT ), an antiretroviral agent, slowed disease progression in HIV-infected asymptomatic patients. To evaluate the efficacy and safety of thymopentin in HIV-infected asymptomatic patients receiving either monotherapy with AZT, didanosine ( ddI ), or stavudine ( d4T ), or combination antiretroviral therapy with AZT / ddI or AZT / zalcitabine ( ddC ). Read More
Last Updated: 22 Jun 2005
Source: Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Treatment Study to assess of safety and efficiency of T cells receptor (TCR) alfa beta depleted graft for hematopoietic stem cell transplantation (HSCT) from haploidentical and unrelated donors in patients with primary immunodeficiency diseases Read More
Last Updated: 22 Jul 2016
Source: University of South Florida
We hypothesize that there is a statistically significant difference in miRNA profiling and expression of subjects with asthma upon its exacerbation compared to patient's baseline level or following effective treatment of an exacerbation of asthma. Therefore, plasma miRNA profiling may provide noninvasive, highly specific and sensitive biomarkers for asthma exacerbation's detection and treatment follow-up. Read More
Last Updated: 05 Oct 2014
Source: The Center for Rheumatic Disease, Allergy, & Immunology
- This is the first study, that we are aware of, that will evaluate the efficacy of IgIV in patients with IgG subclass deficiency. - Will provide data for further collaboration in extending study to involve other immunological centers in the United States to study patients with similar disease. Read More
Last Updated: 28 Dec 2006
Source: Institute of Immunology and Experimental Therapy of the Polish Academy of Sciences
The primary purpose of this experimental therapy is to treat, with the aid of bacteriophages, patients with non-healing postoperative wounds or bone, upper respiratory tract, genital or urinary tract infections in whom extensive antibiotic therapy failed or the use of the targeted drug is contraindicated. Read More
Last Updated: 04 Sep 2013
Source: Rigel Pharmaceuticals
The purpose of this study is to determine the safety, efficacy and tolerability of R940343 in the treatment of mild to moderate asthma. Read More
Last Updated: 04 Aug 2016
Source: Sanjay Gandhi Postgraduate Institute of Medical Sciences
Raynaud's phenomenon (RP) associated with scleroderma is a difficult problem to treat. Many patients develop ischemic digital ulcers due to severe RP that causes considerable morbidity and adversely affects the quality of life. In an earlier study, we have observed marked improvement in RP attacks and rapid healing of digital ulcers following therapy with phosphodiesterase V inhibitor, Tadalafil. In the present multicentric study we aim to study the efficacy ... Read More
Last Updated: 06 May 2010
Page 1 of 50